secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2021-08-03T23:59:59+00:00
Accession:  0001127537-21-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q2 2021 revenue $12.2M (+232% YoY); raises FY guidance to $49-51M
-------------------------------------------------------------------------

- Worldwide revenue $12.2M, up 232% YoY; U.S. revenue $6.6M (+343%), international $5.6M (+157%).
- Gross margin 74% vs 28% a year ago; net loss $12.4M ($0.34 per share) vs $11.9M ($6.15).
- Added 20 new U.S. Zephyr Valve treating centers (total 180); launched Chartis software upgrade.
- FY 2021 revenue guidance raised to $49-51M from $48-50M; OpEx unchanged at $85-90M.
- Cash and marketable securities $211.5M as of June 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753721000037/0001127537-21-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753721000037/lung-20210803.htm
  HTML page:      https://secwatch.observer/filing/0001127537-21-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer